UnitedHealth earned $6.38 a share on an adjusted basis in the second quarter, against the roughly $4.90 analysts polled by LSEG expected — a beat of nearly a dollar and a half. Revenue of $112.03 billion edged past estimates while growing just 0.3% from a year ago. Net income jumped to $5.48 billion from $3.41 billion. Management raised full-year adjusted earnings guidance to $19.50–$20.00 a share, up from the “more than $18.25” it promised in the spring. The stock rose more than 8% Thursday morning — the best gainer in the S&P 500 on a day chip stocks dragged the index down — extending its 2026 gain to roughly 25%.
Read that revenue line again: sales grew 0.3%, profit grew 61%. The engine is the medical cost ratio — the share of premiums paid back out in claims — which fell to 86.7% from 89.4% a year earlier, crushing the 88.47% analysts modeled. CFO Wayne DeVeydt credited tighter cost management in Medicare Advantage, higher Medicaid reimbursement rates, and repricing. The other half of the story is subtraction: UnitedHealth served 48.5 million members, down about 525,000 in three months, and expects to lose roughly 500,000 ACA exchange members and 1.1 million Medicare Advantage members this year as it exits unprofitable contracts and prices plans to make money rather than to grow.
What DeVeydt would not do is declare the cost problem solved. “These results are not a reflection of trend bending or coming under control,” he told reporters, “but rather our efforts to start pushing down what is already an elevated number.” The company is also leaning on a familiar 2026 lever: it has committed roughly $1.5 billion to AI initiatives aimed at payment accuracy, fraud detection, and faster prior authorizations — while stressing the tools do not decide whether treatments get approved. The efficiency-first framing echoes what JPMorgan said about AI cutting entire teams earlier this earnings season.
Our take: This is what “shrink to profitability” looks like when it works: fire your worst customers, reprice the rest, and let software grind down admin costs. The Street is paying for margin, not membership — and after a year of managed-care blowups, a boring beat-and-raise reads like a miracle. Two catches. First, pruning is a one-time lever: once the 1.6 million unprofitable members are gone, growth has to come from somewhere, and DeVeydt himself called the price-hikes-offsetting-shrinkage dynamic “not a good thing for the system.” Second, the cost trend isn’t bent — his words — so the margin gain is execution, not weather. Execution can be copied: if Elevance and Humana show the same playbook working, the whole sector rerates. If they don’t, UnitedHealth’s quarter was a moat, and priced like one at 25% up on the year.
What to watch
- Peer medical cost ratios. Managed-care rivals report over the next two weeks. If their ratios improve too, this is a sector turn; if not, UnitedHealth is simply out-executing — and peers get sold.
- The membership floor. Another 1.1 million Medicare Advantage exits are planned this year. Watch whether the “more than $439 billion” revenue guide survives the shrinking book — DeVeydt says he expects to beat it.
- Second-half cost trend. GLP-1 drugs and elevated utilization are still pushing claims up. A medical cost ratio that holds under 87% through Q4 would prove the guide conservative; a rebound would prove the CFO’s caution right.